In-vitro and in-vivo activities of DW-116, a new fluoroquinolone

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 4, 1997, Pages 509-514

  Choi, Keum Hwa ^a   Hong, Jong Su ^a   Kim, Sook Kyung ^a   Lee, Dug Keun ^b   Yoon, Sung June ^b   Choi, Eung Chil ^a  

^a Seoul National University   (South Korea)

^b DongWha Pharm Ind Co   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FANDOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RUFLOXACIN; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION;

EID: 0030946528     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.4.509     Document Type: Article

References (9)

1. Eliopoulos, G. M. & Eliopoulos, C. T. (1993). Activity in vitro of the quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds.), pp. 161-93. American Society for Microbiology, Washington, DC.
2. Hooper, D. C. & Wolfson, J. S. (1993). Mechanisms of bacterial resistance to quinolones. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson, J. S., Eds.), pp. 97-118. American Society for Microbiology, Washington, DC.
3. Yoon, S. J., Chung, Y. H., Lee, C. W., Oh, Y. S., Choi, D. R. & Kim, N. D. (1996). Novel Quinolone Carboxylic Acid Derivatives. USA Patent no. 5496947-A.6.
4. Lee, W. Y., Hwang, Y., Sung, S., Moon, E., Jung, Y. & Lee, D. (1995). The pharmacokinetic studies of DW-116. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F196, p. 147. American Society for Microbiology, Washington, DC.
5. Cuffini, A. M., Tullio, V., Allocco, A., Paizis, G., De Leo, C. & Carlone, N. A. (1994). Effect of rufloxacin upon non-specific immune defences: in-vitro, ex-vivo and in-vivo results. Journal of Antimicrobial Chemotherapy 34, 545-53.
6. Choi, K. H., Kim, D. J., Shim, J. S., Choi, M. J., Park, N. J., Kim, B. O. et al. (1994). In-vitro and in-vivo activity of DWC-751, a new cephalosporin. Journal of Antimicrobial Chemotherapy 33, 1233-7.
7. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition; Approved Standard M7-A3. NCCLS, Villanova, PA.
8. Cleeland, R. & Squires, E. (1991). Evaluation of new antimicrobials in vitro and in experimental animal infections. In Antibiotics in Laboratory Medicine, 3rd edn (Lorian V., Ed.), pp. 739-86. Williams & Wilkins, Baltimore, MD.
9. Litchfield, J. T. & Wilcoxon, F. (1949). Simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96, 99-113.